Representatives of Fulgent Genetics to Participate in Oppenheimer’s 32nd Annual Healthcare Conference

Rhea-AI Summary

Fulgent Genetics (NASDAQ: FLGT) announced its management team will participate virtually in Oppenheimer’s 32nd Annual Healthcare Conference on March 15, 2022, at approximately 9:20 a.m. Eastern Time. A live webcast of the presentation will be hosted on the company's Investor Relations website, with a replay available one hour after the event.

Fulgent Genetics specializes in technology-driven genetic testing, focusing on patient care in oncology, infectious diseases, rare diseases, and reproductive health. The company offers a flexible test menu and advanced technology for tailored genetic solutions.

TEMPLE CITY, Calif.--(BUSINESS WIRE)-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”) , a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that members of its management team are scheduled to virtually participate in Oppenheimer’s 32^nd Annual Healthcare Conference on Tuesday, March 15, 2022.

These representatives of the company will conduct a presentation beginning at approximately 9:20 a.m. Eastern Time (6:20 a.m. Pacific Time).

A live webcast of the session will be available on the Investor Relations section of the Fulgent Genetics website at ir.fulgentgenetics.com. A replay of the webcast will be accessible at ir.fulgentgenetics.com beginning approximately one hour following the completion of the event.

About Fulgent Genetics

Fulgent Genetics is a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health. Fulgent’s proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy, and competitive turnaround times. Combining next generation sequencing (“NGS”) with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. A cornerstone of the Company’s business is its ability to provide expansive options and flexibility for all clients’ unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated lab services.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220308005481/en/

Investor Relations Contacts:

The Blueshirt Group

Nicole Borsje, nicole@blueshirtgroup.com

Source: Fulgent Genetics, Inc.

FAQ

When is Fulgent Genetics presenting at Oppenheimer's Healthcare Conference?

Fulgent Genetics will present on March 15, 2022, starting at 9:20 a.m. Eastern Time.

How can I watch the Fulgent Genetics presentation?

You can watch the presentation live on Fulgent Genetics' Investor Relations website at ir.fulgentgenetics.com.

Will there be a replay of the Fulgent Genetics conference presentation?

Yes, a replay of the presentation will be available on the website approximately one hour after the event.

What does Fulgent Genetics specialize in?

Fulgent Genetics specializes in technology-based genetic testing for oncology, infectious diseases, rare diseases, and reproductive health.

What is Fulgent Genetics' stock symbol?

Fulgent Genetics' stock symbol is FLGT.